Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2 studies found for:    BIIB033 | Biogen [Lead] | Phase 2
Show Display Options
Rank Status Study
1 Completed
Has Results
BIIB033 In Acute Optic Neuritis (AON)
Condition: Acute Optic Neuritis
Interventions: Biological: BIIB033 (anti-LINGO-1 mAb);   Drug: Placebo
2 Completed Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
Condition: Multiple Sclerosis
Interventions: Drug: BIIB033 (anti-LINGO-1 mAb);   Other: Placebo;   Drug: Interferon Beta-1a

Indicates status has not been verified in more than two years